IS2097B - Lækningameðferð, sem felst í CD 154 hindrun, við lækningaprótínstálmaheilkenni - Google Patents

Lækningameðferð, sem felst í CD 154 hindrun, við lækningaprótínstálmaheilkenni

Info

Publication number
IS2097B
IS2097B IS5274A IS5274A IS2097B IS 2097 B IS2097 B IS 2097B IS 5274 A IS5274 A IS 5274A IS 5274 A IS5274 A IS 5274A IS 2097 B IS2097 B IS 2097B
Authority
IS
Iceland
Prior art keywords
therapeutic
inhibition
contained
protein bar
bar syndrome
Prior art date
Application number
IS5274A
Other languages
English (en)
Other versions
IS5274A (is
Inventor
Adelman Burt
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of IS5274A publication Critical patent/IS5274A/is
Publication of IS2097B publication Critical patent/IS2097B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IS5274A 1997-06-20 1999-11-26 Lækningameðferð, sem felst í CD 154 hindrun, við lækningaprótínstálmaheilkenni IS2097B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20
PCT/US1998/012773 WO1998058672A1 (en) 1997-06-20 1998-06-19 Cd154 blockade therapy for therapeutic protein inhibitor syndrome

Publications (2)

Publication Number Publication Date
IS5274A IS5274A (is) 1999-11-26
IS2097B true IS2097B (is) 2006-04-12

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5274A IS2097B (is) 1997-06-20 1999-11-26 Lækningameðferð, sem felst í CD 154 hindrun, við lækningaprótínstálmaheilkenni

Country Status (25)

Country Link
US (1) US20020119151A1 (is)
EP (1) EP1034001B1 (is)
JP (1) JP2002504910A (is)
KR (1) KR100567998B1 (is)
CN (2) CN1261285A (is)
AT (1) ATE272408T1 (is)
AU (1) AU733062B2 (is)
BG (1) BG64436B1 (is)
BR (1) BR9810755A (is)
CA (1) CA2294138A1 (is)
CZ (1) CZ295805B6 (is)
DE (1) DE69825473T2 (is)
EA (1) EA002512B1 (is)
EE (1) EE9900587A (is)
ES (1) ES2226152T3 (is)
HK (1) HK1031825A1 (is)
HU (1) HUP0002048A3 (is)
IL (1) IL133305A0 (is)
IS (1) IS2097B (is)
NO (1) NO996274L (is)
NZ (1) NZ502051A (is)
PT (1) PT1034001E (is)
SK (1) SK285962B6 (is)
TR (1) TR199903141T2 (is)
WO (1) WO1998058672A1 (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ511034A (en) * 1998-09-21 2004-03-26 American Nat Red Cross Methods of downmodulating the immune response to therapeutic proteins
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
RU2270691C2 (ru) 2000-05-12 2006-02-27 Бет Израел Диконесс Медикал Сентер, Инк. Композиции и способы достижения иммунной супрессии
IES20030298A2 (en) * 2002-04-23 2003-10-29 R Stephen Porter Inhibition of platelet aggregation
ES2353222T3 (es) * 2003-06-13 2011-02-28 Biogen Idec Ma Inc. Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos.
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
EP2239271A1 (en) * 2003-06-13 2010-10-13 Biogen Idec MA Inc. Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
CN1938045B (zh) 2003-11-04 2014-03-26 诺华疫苗和诊断公司 治疗自身免疫和炎性疾病以及器官移植排异的拮抗性抗-cd40抗体的应用
BRPI0513798A (pt) 2004-07-26 2008-05-13 Biogen Idec Inc anticorpos anti-cd154
US20070286855A1 (en) * 2004-08-03 2007-12-13 Mayo Foundation For Medical Education And Research Improving treatments
CA2608750A1 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
EA018301B1 (ru) 2006-04-21 2013-07-30 Новартис Аг Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US9447156B2 (en) 2011-05-17 2016-09-20 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
CZ244399A3 (cs) * 1997-01-10 1999-10-13 Biogen, Inc. Použití sloučeniny anti-CD40L pro výrobu léku pro léčení imunologických onemocnění

Also Published As

Publication number Publication date
NZ502051A (en) 2001-04-27
SK180399A3 (en) 2000-06-12
NO996274D0 (no) 1999-12-17
AU733062B2 (en) 2001-05-03
DE69825473D1 (de) 2004-09-09
ATE272408T1 (de) 2004-08-15
CN1261285A (zh) 2000-07-26
DE69825473T2 (de) 2005-08-04
EP1034001A1 (en) 2000-09-13
SK285962B6 (sk) 2007-12-06
BR9810755A (pt) 2000-08-15
CZ295805B6 (cs) 2005-11-16
HUP0002048A3 (en) 2002-09-30
IS5274A (is) 1999-11-26
CN1651071A (zh) 2005-08-10
EA200000059A1 (ru) 2000-08-28
ES2226152T3 (es) 2005-03-16
JP2002504910A (ja) 2002-02-12
WO1998058672A1 (en) 1998-12-30
IL133305A0 (en) 2001-04-30
PT1034001E (pt) 2004-12-31
HK1031825A1 (en) 2001-06-29
NO996274L (no) 2000-02-18
EA002512B1 (ru) 2002-06-27
BG104092A (en) 2000-10-31
US20020119151A1 (en) 2002-08-29
EP1034001B1 (en) 2004-08-04
CA2294138A1 (en) 1998-12-30
CZ458899A3 (cs) 2000-04-12
AU8153698A (en) 1999-01-04
TR199903141T2 (xx) 2000-09-21
EE9900587A (et) 2000-08-15
KR100567998B1 (ko) 2006-04-07
KR20010013964A (ko) 2001-02-26
BG64436B1 (en) 2005-02-28
HUP0002048A2 (hu) 2000-10-28

Similar Documents

Publication Publication Date Title
IS5274A (is) Lækningameðferð, sem felst í CD 154 hindrun, við lækningaprótínstálmaheilkenni
UA66767C2 (uk) Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
DK0682664T3 (da) Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler
BG102668A (en) Application of ppar-alpha and prar-gamma antagonist for the treatment of syndrome x
AU3419995A (en) Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
WO2001024816A3 (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
SG91925A1 (en) Post treatment of via opening by n-containing plasma or h-containing plasma for elimination of fluorine species in the fsg near the surfaces of the via opening
MY114347A (en) Synergistic therapeutic compositions and methods.
UA72909C2 (en) Cinnamide derivatives useful in the treatment of inflammatory and immune diseases, a composition containing such derivatives and a method for the preparation of cinnamide derivatives
ES2119094T3 (es) Inhibicion de la hemorragia uterina disfuncional.
MXPA04002565A (es) Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
AU5170400A (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
AU3864000A (en) Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
HUP0003679A3 (en) Use of pkc inhibitors for the preparation of pharmaceutical compositions treating cardiovascular diseases
DE69231384D1 (de) Zusammensetzungen zur behandlung des chronischen erschöpfungs-syndroms
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
WO2003099212A3 (en) Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
PL327472A1 (en) Nitrogen oxide (no) synthase inhibitor for use in treatment or polphylaxy of type ii diabetes
IL114808A0 (en) Combination therapy for hiv
NO982853D0 (no) Aminoguanidin for behandling av NIDDM
MX9704579A (es) Composicion farmaceutica que comprende mirtazapina y uno o mas inhibidores selectivos de reabsorcion de serotonina.